Vaxcyte Inc.
PCVXHeld by 14 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying14 funds opened new positions. Next phase3 readout (31 valent pneumococcal conjugate vaccine): Jan 2027. Short interest: 9.8% of float.
Held by 14 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying14 funds opened new positions. Next phase3 readout (31 valent pneumococcal conjugate vaccine): Jan 2027. Short interest: 9.8% of float.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.